



Bristol-Myers Squibb Company
P.O. Box 4000
Princeton, NJ 08543-4000 U.S.A.

RECEIVED
CENTRAL FAX CENTER

DEC 13 2005

Fax

To:	COMMISSIONER FOR PATENTS Examiner Raymond K. Covington Art Group: 1625	From:	Aldo A. Algieri Reg. No. 31,697
Fax:	571-273-8300	Phone:	203-677-6809
Date:	December 13, 2005	Pages:	24, including cover page
Re:	USSN 10/719,187	Docket:	CT2717 - US - NP

The following documents are enclosed:

- (1) Amendment and Reply Under Rule 37 CFR 1.111 (5 pages)
- [2] Amended Claims [3 pages]
- (3) Information Disclosure Statement [1 page with copy]
- (4) PTO-1449 [1 page]
- [5] Reference [12 pages]

CERTIFICATE OF TRANSMISSION UNDER 37 CFR 1.8

I hereby certify that the documents listed above are being transmitted via facsimile to the
United States Patent and Trademark Office on Dec 13, 2005
Date

N. S. Turover
Signature

Nancy S. Turover
Typed name of person signing Certificate

If you do not receive a complete fax, please contact Nancy Turover @ 203-677-7000.

16 pgs out of 24
Received 24 - p.16 cut-off

CASE CT-2717 US - NP

RECEIVED
CENTRAL FAX CENTER

DEC 13 2005

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF Wu, et al.

EXAMINER: Raymond K. Covington

APPLICATION NO: 10/719,187

ART UNIT: 1625

FILED: November 21, 2003

FOR: 3-HETEROCYCLIC BENZYLAMIDE DERIVATIVES AS POTASSIUM
CHANNEL OPENERS

VIA FACSIMILE: 571-273-8300

Commissioner for Patents

P.O. Box 1450,

Alexandria, VA 22313-1450

AMENDMENT AND REPLY UNDER RULE 37 C.F.R. §1.111

Sir:

A shortened statutory period for response to the outstanding Office Action
mailed October 24, 2005, is due January 24, 2006.

Applicant respectfully traverse the rejections and kindly request
reconsideration based on the following amendments and remarks.

IN THE CLAIMS

Claims 1 - 4 and 6 - 8 remain in the application. Claim 6 is amended.

Kindly amend claim 6 by deleting "and neurodegenerative disorders". Also,
please insert "and" after the word anxiety and before the word depression.